Pipelines

(Image: Getty/LightFieldStudios)

Amgen joins neuroscience exodus

By Ben Hargreaves

In third quarter financials, Amgen announces that it will end its R&D efforts in neuroscience to focus on diseases with a ‘large public health impact.

Follow us

Products

View more

Webinars